Bio-Techne Q1 revenue up 4.6% to $299.7M, but net income falls 25.9% to $28.3M amid pending Merck merger

Filed November 6, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 5, 2025 · ~1 min read

Key Changes

• high

  Pending merger with Merck KGaA approved by shareholders on September 23, 2026; expected to close late 2026 or early 2027.

  MD&A: Pending Merger verify on EDGAR →
• high

  Diagnostics and Spatial Biology segment operating margin fell to 7.4% from 11.2% a year ago, a 380 basis point decline.

  MD&A: Segment Margins verify on EDGAR →
• high

  Diluted EPS dropped 25.0% to $0.18, while net income fell 25.9% to $28.3 million.

  Notes: Earnings Per Share verify on EDGAR →